Clinical Trial

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-06-14; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2024-06-21
Trial Details
NCT Number NCT05422690
Lead Sponsor Inova Health Care Services
Conditions Intrahepatic Cholangiocarcinoma
Enrollment 16 participants
Start Date 2024-06-12
Primary Completion 2027-03-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15